By Stephen Nakrosis
Shares of Telomir Pharmaceuticals were trading higher in Wednesday's after-hours market, following the company's report on its Telmor-1 anti-aging and longevity treatment.
After the bell, the company's shares were trading 4.7% higher, at $4.40. The stock finished the day's regular session with a 5.4% loss, closing at $4.20.
Telomir said a study demonstrated significant age-reversal effects in aging model organisms treated with Telomir-1. Effects included an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 20, 2024 18:44 ET (23:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.